@inbook{6a9347cc50cd4b30b4756f9240a9ab6a,
title = "Activin receptor modulation",
abstract = "Conventional treatment regimen of lower-risk MDS with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that frequently harbor defects in late-stage erythroblasts downstream of erythropoietin action. Thus, alternative treatment options that would achieve sustainable transfusion independence are needed. In this chapter, we will discuss activin receptor ligand traps as novel therapeutic strategies for low-risk MDS subgroups that were recently shown to alleviate anemia by specifically inhibiting aberrant TGF-β signaling and thereby promoting erythroid differentiation.",
author = "Anna Mies and Amit Verma and Uwe Platzbecker",
note = "Funding Information: Acknowledgments This work was supported by the Jos{\'e} Carreras Foundation (DJCLS R13/15) and a grant from the German Research Foundation (SFB655) (UP). Publisher Copyright: {\textcopyright} 2018, Springer International Publishing AG, part of Springer Nature.",
year = "2018",
doi = "10.1007/978-3-319-76879-3_7",
language = "English (US)",
series = "Hematologic Malignancies",
publisher = "Springer Verlag",
pages = "97--104",
booktitle = "Hematologic Malignancies",
}